RecruitingNCT06461351
Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection
A Long Term Follow-up Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection
Sponsor
Juventas Cell Therapy Ltd.
Enrollment
1,000 participants
Start Date
Mar 30, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This clinical trial adopts an observational research method to conduct annual follow-up and monitoring of patients receiving treatment with Inaticabtagene Autoleucel Injection after its commercialization, in order to evaluate the delayed adverse events of Inaticabtagene Autoleucel Injection.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Agree to sign an informed consent form for long-term follow-up studies.
- Registered clinical trial patients with different indications for this product who have received at least one infusion of Inaticabtagene Autoleucel Injection in the past, as well as post market commercialized patients.
Exclusion Criteria1
- \- None.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERInaticabtagene autoleucel Injection
Inaticabtagene autoleucel Injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06461351